I114

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	,	 -		•
Choot	1 4	of	1 2	

	Complete if Known		
Application Number	09/904,180 RECEI	VCD	
Filing Date	July 11, 2001	VEU	
First Named Inventor	Keith D. Allen		
Art Unit	1636	2002	
Examiner Name	Pappu, Site Gall Control		
Attorney Docket Number	Pappu, Site 6 H CENIER 1	600/2000	

	U.S. PATENT DOCUMENTS						
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Examiner	Cite No.1	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	L	US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-	<u> </u>				
		US-					

FOREIGN PATENT DOCUMENTS							
Examiner Cite Foreign Patent Docum		eign Patent Document			Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Number ⁴ Country Code ³ (# known)		Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
89	Α	wo	97/14797	4/24/97	Dana Farber Cancer Institute	Page 19	
88	В	wo	98/54307	12/3/98	Schering AG	Whole document	

Examiner Signature Date Considered 1/4/02				
	1	Examiner Signature	D Sulan-	1/4/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ **Applicant's** unique citation designation number (**optional**). ² See Kind Codes of U.S. Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

PTO/SB/08B (10-01)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/904,180 Application Number Filing Date July 11, 2001 First Named Inventor Keith D. Allen

(use as many sheets as necessary)

Art Unit 1636 **Examiner Name** Pappu, Sita S.

Sheet 2 of 2 R-477 Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *			T 2			
DE	С	F. TSUI et al, "Mouse Cysteine Proteinase Inhibitor (MS2) mRNA Sequence" Database EMBL Online, May 18, 1998, retrieved from E.B.I., Hinxton, U.K., Database Accession No. M92418 (XP002212903), 1 page				
PS	D	L. PENNACCHIO et al., "PROGRESSIVE ATAXIA, MYOCLONIC EPILEPSY AND CEREBELLAR APOPTOSIS IN CYSTATIN B-DEFICIENT MICE" Nature Genetics, Vol. 20, November 1998, pp. 251-258				
\$8	E	F. TSUI et al., "MOLECULAR CHARACTERIZATION AND MAPPING OF MURINE GENES ENCODING THREE MEMBERS OF THE STEFIN FAMILY OF CYSTEINE PROTEINASE INHIBITORS" Genomics, Vol. 15, pp. 507-514 (1993)				

Examiner Signature	D Sullivan	Date Considered	114/02

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.